Diligence memo · auto-generated · as of July 2, 2026
Pharmatrophix Inc
Pharmatrophix Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pharmatrophix Inc operates in Pharmaceuticals, based in RALEIGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pharmatrophix Inc has raised $17M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2014-06-27.
Most recent recorded round closed around 2014-06-27.
Valuation (modeled)modeled
Provath models Pharmatrophix Inc at approximately $319M (range $12M–$1.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.62× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 12.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 63% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Aquinox Pharmaceuticals (Usa) Inc, Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, Minnesota Medical Solutions LLC.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.